ReviewTrends in cardiovascular medicine2020
Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity.
Review in Trends in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05882578 (Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- The effects of combined aerobic and resistance exercise on metabolic blood biomarkers and quality of life in patients with breast cancer: a systematic review meta-analysis.Frontiers in oncology · 2026Pooled it
- Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials.Heart failure reviews · 2021Pooled it
- Supervised high-intensity interval training reduces the negative effect of chemotherapy on cardiorespiratory fitness in young breast cancer women: a randomised controlled study.European journal of applied physiology · 2025Trial
- Burden of cardiovascular diseases in breast cancer survivors: a 9-year retrospective cohort study based on regional medical data in Inner Mongolia China.Cardio-oncology (London, England) · 2026Article
- Osthole attenuates trastuzumab-induced cardiotoxicity in mice by enhancing autophagy via regulating the p38MAPK/mTOR signaling pathway.Journal of traditional and complementary medicine · 2026Article
- Cancer as a novel risk factor for major cardiovascular adverse events in secondary prevention.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Prefectural Survey on Anthracycline-Related Cardiomyopathy at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4.Circulation reports · 2025Article
- Exercise-induced βBrain, behavior, and immunity · 2025Article
- Effect of chemotherapy and different chemotherapeutic regimens on electrocardiographic parameters in breast cancer women: a retrospective and within-subject longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Cardio-Oncology and Breast Cancer Therapies.Current treatment options in oncology · 2025Review
- PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages.Scientific reports · 2025Article
- A retrospective analysis of the association of obesity with anthracycline- and trastuzumab-induced cardiotoxicity in the treatment of breast cancer and lymphoma.Archives of medical science : AMS · 2025Article
- Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.Cancer medicine · 2025Article
- Novel models by machine learning to predict the risk of cardiac disease-specific death in young patients with breast cancer.Discover oncology · 2024Article
- Cardioprotective strategies in the management of chemotherapy-induced cardiotoxicity: current approaches and future directions.Annals of medicine and surgery (2012) · 2024Review
- Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community.Breast cancer (Tokyo, Japan) · 2024Observational
- Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.Journal of translational internal medicine · 2024Article
- Licochalcone A alleviates ferroptosis in doxorubicin-induced cardiotoxicity via the PI3K/AKT/MDM2/p53 pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model.World journal of gastrointestinal oncology · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Breast cancer is the most common malignancy affecting females, with over 260,000 new cases annually and over 3.1 million survivors in the United States alone. Exposure to potentially cardiotoxic therapies, including anthracyclines, trastuzumab, and radiation therapy, coupled with host factors, place patients at increased risk for the development of cardiovascular disease (CVD) compared to non-cancer controls. Overall survival outcomes are significantly worse in patients who develop CVD, and in certain breast cancer populations, cardiovascular death exceeds the risk of cancer death in the long-term. In order to mitigate the risk of CVD, there is a growing interest in the use of cardioprotective strategies at the time of cancer therapy initiation. In this review, we present a detailed evaluation of the evidence from recently completed as well as ongoing cardio-oncology clinical trials in pharmacologic cardioprotection in breast cancer patients. We focus primarily on the potential role of dexrazoxane, alterations in anthracycline dosing or formulation, neurohormonal antagonists, beta-blockers, and combination therapy. We also discuss ongoing studies in statin cardioprotection, radiation delivery strategies, use of risk-guided strategies and the study of specific cancer populations. We close with a discussion of the ongoing needs in the field of cardio-oncology in order to advance the clinical care of patients with rigorous, evidence-based medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.